Lipids and lipoproteins in women

被引:40
作者
OBrien, T
Nguyen, TT
机构
[1] Division of Endocrinology, Metabolism, Nutrition and Internal Medicine, Mayo Clinic Rochester, Rochester, MN
[2] Endocrine Research Unit, Mayo Clinic Rochester, Rochester, MN 55905
关键词
D O I
10.4065/72.3.235
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coronary artery disease (CAD) is the most common cause of death in women in the United States, Dyslipidemia is a risk factor for CAD in both men and women, Low levels of high-density lipoprotein (HDL) cholesterol and hypertriglyceridemia, especially in association with a dense low-density lipoprotein (LDL) phenotype, may be of greater importance in women than in men, The relationship between CAD and dyslipidemia and the therapeutic approach to disorders of lipid metabolism in women have unique features because of the effects of exogenous and endogenous hormones on lipid pathways, Estrogen decreases LDL cholesterol and Lp(a) lipoprotein and increases triglyceride and HDL cholesterol levels, Progestogens decrease triglycerides, HDL cholesterol, and Lp(a), and they increase LDL cholesterol, Thus, oral contraceptives increase plasma triglycerides, whereas the effect of these agents on LDL cholesterol and HDL cholesterol levels is related to the androgenicity and dose of progestogen, Postmenopausal hormone replacement therapy increases triglycerides and decreases LDL cholesterol, The effect of hormone replacement therapy on HDL cholesterol is influenced by the addition of progestogen, Although no primary prevention studies have analyzed lipid lowering and CAD in women, secondary prevention studies have suggested that the response to drug treatment and the benefit of lipid lowering are similar in women and in men, Hormone replacement therapy should be considered in the treatment of hypercholesterolemia in postmenopausal women; however, individualization of treatment is important to avoid adverse effects.
引用
收藏
页码:235 / 244
页数:10
相关论文
共 106 条
  • [21] DIFFERENCES IN LOW-DENSITY LIPOPROTEIN SUBFRACTIONS AND APOLIPOPROTEINS IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN
    CAMPOS, H
    MCNAMARA, JR
    WILSON, PWF
    ORDOVAS, JM
    SCHAEFER, EJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (01) : 30 - 35
  • [22] INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY
    CASTELLI, WP
    GARRISON, RJ
    WILSON, PWF
    ABBOTT, RD
    KALOUSDIAN, S
    KANNEL, WB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20): : 2835 - 2838
  • [23] THE TRIGLYCERIDE ISSUE - A VIEW FROM FRAMINGHAM
    CASTELLI, WP
    [J]. AMERICAN HEART JOURNAL, 1986, 112 (02) : 432 - 437
  • [24] TRANSDERMAL ESTRADIOL AND CARDIOVASCULAR RISK-FACTORS
    CHEANG, A
    SITRUKWARE, R
    SAMSIOE, G
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1994, 101 (07): : 571 - 581
  • [25] A DOSE-RESPONSE RELATIONSHIP BETWEEN SEX HORMONE-INDUCED CHANGE IN HEPATIC TRIGLYCERIDE LIPASE AND HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL IN POSTMENOPAUSAL WOMEN
    COLVIN, PL
    AUERBACH, BJ
    CASE, LD
    HAZZARD, WR
    APPLEBAUMBOWDEN, D
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1991, 40 (10): : 1052 - 1056
  • [26] CORSON SL, 1993, INT J FERTIL, V38, P79
  • [27] CREMER P, 1994, EXCERPTA MED INT C S, V1066, P903
  • [28] RISK-FACTORS FOR ACUTE MYOCARDIAL-INFARCTION IN WOMEN - EVIDENCE FROM THE ROYAL-COLLEGE-OF-GENERAL-PRACTITIONERS ORAL CONTRACEPTION STUDY
    CROFT, P
    HANNAFORD, PC
    [J]. BRITISH MEDICAL JOURNAL, 1989, 298 (6667) : 165 - 168
  • [29] Dahlen G H, 1988, Prog Clin Biol Res, V255, P27
  • [30] ASSOCIATION OF LEVELS OF LIPOPROTEIN LP(A), PLASMA-LIPIDS, AND OTHER LIPOPROTEINS WITH CORONARY-ARTERY DISEASE DOCUMENTED BY ANGIOGRAPHY
    DAHLEN, GH
    GUYTON, JR
    ATTAR, M
    FARMER, JA
    KAUTZ, JA
    GOTTO, AM
    [J]. CIRCULATION, 1986, 74 (04) : 758 - 765